Эффективность комбинированной антигипертензивной терапии, основанной на моксонидине, у больных с метаболическим синдромом
Диссертация
В рекомендациях Европейского Общества Кардиологов, Европейского Общества по Артериальной Гипертензии от 2007 г., Всероссийского Научного Общества Кардиологов от 2010 г. МС включен в стратификацию риска сердечно-сосудистых заболеваний. Наличие у больного с МС сопутствующей артериальной гипертонии (АГ) позволяет оценить риск как высокий и очень высокий даже при высоком нормальном артериальном… Читать ещё >
Список литературы
- «Новые возможности в лечении больных с метаболическим синдромом. Результаты исследования АЬМА2″. Чазова И. Е., Мычка В. Б. Системные гипертензии, 2006, том 8, № 2
- Салтыкова М.М., Рогоза А. Н., Ощепкова Е.В и др. Проблемы индексации миокарда ЛЖ на размеры тела у пациентов с избыточной массой тела, Терапевтический архив, 2006, № 9, с.92−95
- Агеев Ф.Т. Эволюция представлений о диастолической функции сердца. Сердечная недостаточность 2000, Т.1, № 2, С.48−50
- Агеев Ф.Т., Орлова Я. А., Нуралиев Э. Ю. и др. Скорость пульсовой волны предиктор развития сердечно-сосудистых осложнений у мужчин с ишемической болезнью сердца. Кардиол. вестн. 2007- 2(1): 178—183
- Алексанян Л.А., Полосьянц О. Б. Моксонидин в современном лечении кардиоваскулярных заболеваний. РМЖ 2010 г, том 18, № 18
- Арутюнов Г. П., Оганезов Л. Г. Гиперфильтрация у больных с артериальной гипертонией: результаты эпидемиологических исследования. Тер. архив. 2009- 8: 24−30
- Барац С.С., Закроева А. Г. Диастолическая функция по показателям трансмитрального кровотока и потока в легочных венах: дискуссионные вопросы патогенеза, терминологии и классификации //КардиолоОгия 1998. № 5. с.69−73
- Беленков Ю.Н., Агеев Ф. Т., Мареев В. Ю. Знакомьтесь: диастолическая сердечная недостаточность. Сердечная недостаточность 2000, Т. 1, № 2, С. 4044
- Беленков Ю.Н., Агеев Ф. Т., Мареев В. Ю. Знакомьтесь: диастолическая сердечная недостаточность. Сердечная недостаточность 2000, Т. 1, № 2, С. 4044
- Беленков Ю.Н., Мареев В. Ю. Сердечно-сосудистый континуум. Сердечная недостаточность 2002, Т. 3, № 11, С. 7−11
- Беленков Ю.Н., Мареев В. Ю., Агеев Ф. Т. Ингибиторы ангиотензин-превращающего фермента в лечении сердечно-сосудистых заболеваний / М., 2001.-С. 39−44
- Бойцов С.А. Сердце как орган-мишень при артериальной гипертонии в книге Руководство по артериальной гипертонии, Москва, Медиа Медика, 2005 с. 201−217.
- Бондарь И.А., Климонтов В. В., Симакова А. И. Ожирение и хроническая болезнь почек. Терапевтический архив 2011- № 6
- Бузиашвили Ю. И, Ключников И. В, Мелконян A.M. и др. Ишемическое ремоделирование левого желудочка (определение, патогенез, диагностика, медикаментозная и хирургическая коррекция). Кардиология, 2002, № 10, С. 8894.
- Бусарова Е.С., Вершинина A.M., Гапон Л. И. и др. Влияние терапии фозиноприлом в сочетании с ГХТ на основные показатели жесткости артерий у пациентов с артериальной гипертонией при метаболическом синдроме. Терапевтический архив № 4 2005
- Вигдорчик В.И., Прокопенко В. Д., Симонов Д. В. Диастолическая функция левого желудочка сердца у больных артериальной гипертензией, ассоциированной с метаболическим синдромом. Вестник новых мед. технологий 2004- 4. т1 I.e.57−59
- Демидова Т.Ю., A.C. Аметов, Л. В. Смагина. Моксонидин в коррекции метаболических нарушений и эндотелиальной дисфункции у больных сахарным диабетом типа 2, ассоциированным с артериальной гипертензией. Артер. гипертензия. 2004. — Т. 10, № 2. — С. 104−109
- Дорофеева Г. Б., Дорофеев В. И., Носова H.H. Взаимосвязь ИР и гиперактивности СНС при MC: современные методы коррекции. Cons. Med. 2009, Том И, № 10: 48−53
- Дядык А.И., Багрий А. Э., Цыба И.Н.и др. Регресс гипертрофии левого желудочка сердца у больных с эссенциальной артериальной гипертензией и сахарным диабетом под влиянием моксонидина
- Жаринов ОИ, Антоненко ЛН. Нарушение расслабления миокарда: патогенез и клинической значение. Кардиология 1995, № 4, С. 57−60
- Иваненко В.В., Ротарь О. П., Дубровская О. Б. и др. Динамика показателей сосудистой жесткости и центрального давления на фоне длительной антигипертензивной терапии. Артериальная гипертензия 2011- № 3
- Иванов АП, Выжимов ИА. Ремоделирование ЛЖ у больных артериальной гипертонией. Клиническая медицина 2006, № 5, С. 38−41
- Кардиоваскулярная профилактика. Национальные рекомендации. Всероссийское научное общество кардиологов. Москва, 2011
- Карпов Ю.А. Применение антагонистов кальция у больных артериальнойгипертонией и ишемической болезнью сердца: современное состояние вопроса / Кардиология. 2000. — № 10. — С. 52−55
- Клиническая фармакология / Под ред. В. Г. Кукеса, издание 4, М.: ГЭОТАР-Медиа, 2008- 392−395
- Конечная У.Я., Нанчикеева M.J1., Гладкая A.A. и др. Значение показателей внутрипочечной гемодинамики у пациентов с эссенциальной артериальной гипертонией. Ультразвуковая и функциональная диагностика. 2001. № 2: 83−89
- Конради А. О. Жукова A.B., Винник Т. А. и др. Структурно-функциональные параметры миокарда у больных гипертонической болезнью в зависимости от массы тела, типа ожирения и состояния углеводного обмена. Артериальная гипертензия 2002,8 1 12−17
- Кочкина М.С., Затейщиков Д. А., Сидоренко Б. А. Измерение жесткости артерий и ее клиническое значение // Кардиология, 2005- № 1:63−71
- Краснова Е.А., Моисеев C.B., Фомин В. В. Нефрологические аспекты проблемы ожирения. Клин мед. 2005- 4: 9−14
- Кутырина И.М., Шестакова М. В., Савельева С. А. и др. Вклад ожирения в поражении почек у больных с сахарным диабетом 2 типа. Терапевтический архив. 2010.-N 6.-С.21−25
- Мамедов М.Н. Руководство по диагностике и лечению метаболического синдрома. М.: Мультипринт, 2005.
- Мамедов М.Н., Киселева Н. В., Оганов Р. Г. Значение суммарного коронарного риска у больных с метаболическим синдромом: влияние 8-недельной монотерапии эналаприлом // Кардиоваскулярная терапия и профилактика. 2004. — № 3 (1). — С. 66−71
- Мартынов А., Остроумова О., Мамаев В. и др. Новое поколение препаратов центрального действия в лечении артериальной гипертензии -агонист имидазолиновых рецепторов моксонидин (физиотенз) // Рос. кардиол. журн. 2000. — № 4. — С. 22−27
- Милягин В.А., Шпынев К. В., Шпынева З. М. и др. Особенности центрального и периферического артериального давления у больных артериальной гипертонией. Кардиология 2008: Материалы 10-го Юбилейного научно-образовательного форума.- М., 2008.- С. 67
- Мычка В.Б., Масенко В. П., Флегонтова Н. В. и др. Метаболические эффекты и органопротективное действие периндоприла у больных с метаболическим синдромом. Кардиоваск. Тер. И проф. 2007- 6(2): 34−41
- Мычка В.Б., Масенко В. П., Чазова И. Е. Артериальная гипертония на фоне избыточного веса: особенности терапевтического подхода. Обзоры клинической кардиологии, 2006- № 7
- Мычка В.Б., Тишина Е. В., Жернакова Ю. В. Значение агониста имидазолиновых рецепторов моксонидина в лечении больных артериальной гипертонией и метаболическим синдромом. Результаты исследования MERSY в России. Системные гипертензии 2010- № 1
- Н.А.Мухин, В. В. Фомин, С. В. Моисеев и др. Микроальбуминурия -интегральный маркер кардиоренальных взаимоотношений при артериальной гипертонии. Consilium Medicum, 2007−9:5: 13−19
- Недогода C.B., Барыкина И. Н., Брель У. А. и др. Возможность коррекции Равелом CP факторов риска при артериальной гипертонии на фоне ожирения. Системные гипертензии. 2007, том 9, № 1
- Недогода C.B., Барыкина И. Н., Брель У. А. и др. Возможность коррекции Равелом SR факторов риска при артериальной гипертензии на фоне ожирения. Коне. Медикум укр., 2008, № 5
- Никитин Н.П., Клиланд Джон Дж.Ф. Применение тканевой миокар-диальной допплерэхокардиографии в кардиологии, Кардиология 2002, № 3, С.66−79
- Новиков В.И. и др. Оценка диастолической функции сердца и ее роль в развитии сердечной недостаточности. Кардиология 2001, № 2, С. 78−85
- Новикова М.С., Шилов Е. М., Борисов В. В. Гиперфильтрация ранний признак развития хронической болезни почек у мужчин с метаболическим синдромом. Тер. архив. 2010- 4: 52−56
- Овчинников А.Г. Ожирение и сердечно-сосудистая система, ж."Сердце».т.4,№ 5,(23) 2005.с.243−253
- Оганов Р.Г., Александров A.A. Гиперннсулинемия и артериальная гипертония: возвращаясь к выводам United Kingdom Prospective Diabetes Study. РМЖ, Том 10, № 11, 2002
- Окороков A.H. Диагностика и лечение болезней внутренних органов. М., Мед. лит. 2007
- Остроумова О.Д., Головина О. В., Ролик Н. Л. Органопротективный эффект антигипертензивных препаратов: имеет ли это значение для клинической практики? Consilium Medicum. 2004. — № 5 (6). — С. 344−353
- Остроумова О.Д., Зыкова A.A. Лечение артериальной гипертонии при метаболическом синдроме. Трудный пациент. 2011, № 12
- Остроумова О.Д., Степура О. Б., Бондарец О. В. Комбинация ингибитора ангиотензинпревращающего феремента и диуретика: оптимизация эффективности и безопасности. Системные гипертензии. 2010- 3: 42−45
- Парахонский А.П., Соболевская Г. А. Влияние моксонидина на субфракции липидов и чувствительность к инсулин у больных с АГ./ Успехи современного естествознания. -2008. № 7 — С. 136−137
- Преображенский Д.В., Сидоренко Б. А., Алехин М. Н. и др.Гипертрофия ЛЖ при гипертонической болезни, части 1и 2 в № 10,2003, с. 99−104. и № 11,с.98−101
- Рогоза А.Н., Балахонова Т. В., Чихладзе Н. М. и др. Современные методы оценки состояния сосудов у больных артериальной гипертонией. Москва. 2008: 72с
- Рогоза А.Н., Лазарева Н. В., Зелвеян П. А. и др. Показатели статической и динамической прессорной нагрузки (по данным суточного мониторирования АД) и функциональное состояние почек у больных гипертонической болезнью. Кардиология 2011.-N 4.-С.31−38
- РудомановО.Г., Захаров Д. В. и др. Варианты ремоделирования сердца при ГБ распространенность и детерминанты, Тер. архив 2005 № 9 с. 8−16
- Рухинина Н.К., Ткачева О. Н. Амлодипин: возможности сниежния риска осложнений артериальной гипертонии. Системные гипертензии. 2009- № 4: 1518
- Сагинова Е.А., Галлямов М. Г., Северова М. М. и др. Роль лептина, адипонектина и маркеров инсулинорезистентности в развитии ранних стадий хронической болезни почек и атеросклероза сонных артерий у больных с ожирением. Терапевтический архив 2011- № 6
- Сагинова Е.А., Федорова Е. А., Фомин В. В. и др. Формирование поражения почек у больных ожирением. Тер. арх. 2005- 5: 36−41
- Саидова М.А., Сергакова JI.M., Атауллаханова Д. М. и др. Современные эхокардиографические подходы к оценке гипертрофии миокарда и структурного состояния левого желудочка у больных артериальной гипертонией. М, 2007, 28с.
- Секция артериальной гипертонии ВНОК. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации. М., 2010
- Ткачева О.Н., Барабашкина А. В., Новикова И. М. и др. Изучение эффектов комбинации рамиприла и амлодипина у пациентов с артериальной гипертензией и сахарным диабетом 2-го типа. Кардиология. 2009- 5: 40−7
- Ткаченко С.Б., Берестень Н. Ф. Тканевое допплеровское исследование миокарда, Москва, 2006. с.60
- Упницкий А.А. Обзор исследований с амлодипином при артериальной гипертонии. Consilium Medicum. Том 12, № 5: 36−41
- Чазова И. Е, Мычка В. Б., Беленков Ю. Н. Эффективность квинаприла у больных с множественными факторами сердечно-сосудистого риска (результаты Российского многоцентрового рандомизированного исследования ЭКО) Кардиоваск. тер. и проф. 2004- 3 (6), ч. 1:45−51
- Чазова И.Е., Мычка В. Б. Метаболический синдром. Медиа Медика, 2008
- Чазова И.Е., Ратова Л. Г. Антагонисты кальция в лечении артериальной гипертонии (исследование ЭТНА). Системные гипертензии. 2005- 1: 25−8
- Чазова И.Е., Ратова Л. Г. Диуретики в лечении больных АГ. Системные гипертензии. 2009- № 4: 9−12
- Чазова И.Е., Ратова Л. Г. При всем богатстве выбора другой альтернативы нет. Исследование ЭТНА Плюс (ЭТНА в жизни врача поликлиники). Системные гипертензии. 2008- 2: 35−9
- Шарипова Г. Х. особенности поражения органов-мишеней у больных артериальной гипертонией в зависимости от наличия и отсутствия метаболического синдрома. Диссертация на соискание ученой степени доктора медицинских наук. М., 2009.
- Шляхто Е.В., Конради А. О. Зачем и как лечить гипертрофию левого желудочка? Артериальная гипертензия. 2002- том 8- № 2
- Abellan J, Leal M, Hernandez-Menarguez F, et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl 2005 Jan- 67 Suppl. 93: S20−4
- Aceros H, Farah G, Cobos-Puc L et al. Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 МАРК and Akt. Br J Pharmacol. 2011 Oct-164(3):946−57
- Agabiti-Rosei E, Muiesan ML, Salvetti M. Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy. J Am Soc Nephrol. 2006 Apr- 17(4 Suppl 2):S 104−8
- Agabiti-Rosei E., Muiesan M.L. Hypertensive left ventricularhypertrophy: pathophysiological and clinical issues // Blood Pressure. 2001. — Vol. 10, № 5−6. -P. 288−298
- Agrawal B, Wolf K, Berger A et al. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996- 10: 550−5
- Ahn MS, Kim JY, Youn YJ et al. Cardiovascular parameters correlated with metabolic syndrome in a rural community cohort of Korea: the ARIRANG study. J Korean Med Sei. 2010 Jul- 25(7): 1045−52
- Alpert M.A. Obesity cardiomyopathy: pathophysiology and evolution of clinical syndrome Am.J.Med.Sci.2001- 32- 225−236
- Amador N, de Jesus Encarnacion J, Rodriguez L et al. Relationship between left ventricular mass and heart sympathetic activity in male obese subjects. Arch Med Res 2004−35:411−415
- Amann K, Greber D, Gharehbaghi H et al. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Am J Hypertens 1992−5: 76−83
- Ames RP, Hill PH. Antihypertensive therapy and risk of coronary heart disease. J Cardiovasc Pharmacol 1982- 4 (Suppl. 2): S 206−16
- Ames RP. Negative effect of diuretic drugs on metabolic risk factors of coronary heart disease: possible alternative drug therapies. Amer J Cardiol 1983- 51: 632−8
- Aparina T, Britov A, Gomazkov O. Effects of enalapril and moxonidine on left ventricular hypertrophy in relation to insulin resistance in hypertensive patients. J Hypertens 2003 Jun- 21 Suppl. 4: 75
- Arcaro G, Cretti A, Balzano S et al. Insulin Causes Endothelial Dysfunction in Humans. Circulation. 2002- 105: 576−582
- Asmar R., Topouchian J., Pannier B. et al. Pulse wave velocity as endpoint in large-scale intervention trial. The COMPLIOR study. J Hypertens 2001−19:813−818
- Asmar R.G., Pannier B., Santoni J.Ph., Lauren S. et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation, 1988- 78: 941−950
- Avolio AP, Deng FQ, Li WQ et al. Effects of agingon arterial distensibility in populations with high and low prevalense of hypertension: Comparison between urban and rural communities in China. Circulation 1985: 71: 202−210
- Ayodele OE, Alebiosu CO, Akinwusi PO et al. Target organ damage and associated clinical conditions in newly diagnosed hypertensives attending a tertiary health facility. Niger J Clin Pract. 2007 Dec- 10(4):319−25
- Azevedo J, Garcia Fernandez M. A, Moreno M et al. Heterogeneity of the wall motion velocity pattern and regional left ventricular myocardial function in a normal population. A pulsed Doppler tissue quantitative study. J Am Soc Echo- 1996−9:3:402:801E
- Aznaouridis KA, Stamatelopoulos KS, Karatzis EN et al. Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients. J Hum Hypertens 2007- 21: 654−63
- Bajraktari G, Koltai MS, Ademaj F et al: Relationship between insulin resistance and left ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2 diabetes. Int J Cardiol 2006- 110: 206−211
- Bakuridze KA, Gongadze NV. The modulatory influence of moxonidine on the different link of sympatho-adrenal system and hemodynamic reactions in normo and hypertensive rats during emotional stress. Georgian Med News. 2006 Apr-(133):120−4
- Barbieri A, Bursi F, Mantovani A et al. Left ventricular hypertrophy reclassification and death: application of the Recommendation of the American Society of echocardiography/ European Association of echocardiography. Eur J Echocard. doi: 10.1093
- Barouch LA, Berkowitz DE, Harrison RW et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003- 108:754−759
- Barouch LA, Berkowitz DE, Harrison RW et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003,108:754−759
- Bauer JH, Brooks CS, Weidmann I et al. Effects of diuretic and propranolol on plasma lipoprotein lipids. Clin Pharmacol Ther 1981- 30: 35−43
- Bella JN, Devereux R. B, Roman A Relations of left ventricular mass to fat-free body mass: the strong heart study. Circulation 1998−98, 2538−2544
- Berkin K.E., Ball S.G. Essential hypertension: the heart and hypertension // Hypertension. 2001. — Vol. 86. — P. 467−475
- Blacher J., Guerin A.P., Pannier B. et al. Aortic Pulse Wave Velocity as a Marker of Cardiovascular Risk in Hypertensive Patients. Hypertension, 1999- 33: 1111−1117
- Bonnet F, Marre M, Halimi JM et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens 2006- 24 (6): 1157−63
- Brahimi M, Le Clesiau H, Ouazen Z et al. Microalbuminuria, a marker of artery rigidity and cardiac dysfunction. Arch Mai Coeur Vaiss. 2007 Aug-100(8):673−6)
- Brands MW, Mizzelle HL, Gaillard CA et al. The hemodynamic response to chronic hyperinsulinemia in conscious dog. Am O Hypertens 1991- 4: 164−8
- Braz Nogueira J. Regression of left ventricular hypertrophy in hypertension— does it reduce cardiovascular risk Rev Port Cardiol 2005- 24: 1007 1013
- Briest W, Homagk L, Rassler B et al. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension 2004- 44: 410 418
- Budimir D, Jeroncic A, Gunjaca G et al. Sex-specific association of anthropometric measures of body composition with arterial stiffness in a healthy population. Med Sci Monit. 2012 Feb 1−18(2):CR65−71
- Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000- 36 (3): 446−467
- Calderone A, Thaik CM, Takahashi et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998- 101: 812−818
- Cao C, Kang CW, Kim SZ et al. Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy. Am J Physiol Heart Circ Physiol 2004- 287 (1): HI50−6
- Casale P.N. Devereux R.B.Miner M et al. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann.Inetrn. Med. 1986. 105- 173−178.
- Cassis L.A. Role of angiotensin II in brown adipose thermogenesis during cold acclimation. Am J Physiol Endocrinol Metab 1993- 265: 860−5
- Cassis L.A., Dwoskin L.P. Presynaptic modulation of neurotransmitter release by endogenous angiotensin II in brown adipose tissue. J Neural Transm 1991- 34: 129−37
- Celik A, Ozt^etin M, Yerli Y et al. Increased aortic pulse wave velocity in obese children. Turk Kardiyol Dern Ars. 2011 Oct-39(7):557−62
- Cerasola G, Cottone S, Mule G et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996- 14 (7): 91 520
- Cernes R, Zimlichman R, Shargorodsky M. Arterial elasticity in cardiovascular disease: focus on hypertension, metabolic syndrome and diabetes. Adv Cardiol. 2008−45:65−81
- Chagnac A., Weinstein T., Herman M. et al. The effects of weight loss on renal function in patients with severe obesity. Am. Soc. Nephrol. 2003- 14: 1480−1486
- Chalmers J, Chapman N. Challenges for the prevention of primary and secondary stroke: the importance of lowering blood pressure and total cardiovascular risk. Blood Press. 2001. Vol.10.- P.344−351
- Chang Y, Yoo T, Ryu S et al. Abdominal obesity, systolic blood pressure, and microalbuminuria in normotensive and euglycemic Korean men. Int J Obes (Lond) 2006- 30 (5): 800−4
- Chinali M, Devereux RB, Howard BV et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol. 2004−93:4014
- Chrysant S.G. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch. Intern. Med.- 1994, — Vol.154.- P.737−743
- Cirillo M, Senigalliesi L, Laurenzi M et al. Microalbuminuria in nondiabetic adults- relations of blood pressure, body mass index, plasma cholesterol levels and smoking. The GUBBIO Population Study. Arch Inter Med. 1998- 158 (17): 1933−193
- Collins, R, Peto, R, MacMahon S, et al. Blood pressure, sroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. // Lancet. 1990 Vol.335.-P.827
- Crandall D.L., Armellino D.C., Busier D.E. et al. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 1999- 140: 154−8
- Curb JD, Pressel Sz, Cutler JA. et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension.// JAMA.- 1996, — Vol.276 (23).- P. 1886−1892
- Cushman WC, Materson BJ, Williams DW et al. Pulse Pressure Changes With Six Classes of Antihypertensive Agents in a Randomized, Controlled Trial. Hypertension. 2001- 38: 953−957
- Cuspidi C, Meani S, Fusi V et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004- 22:1991−1998
- Cuspidi C, Meani S, Valerio C et al. Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens. 2007 Mar-20(3):296−303
- Dahlof B., Devereux R. B, Kjedsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002- 359- 995−1003
- Darimont C., Vassaux G., Ailhaud G et al. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 1994- 135: 2030−6
- Davies J, Parker K, Francis D. What is the role of the aorta in directing coronary blood flow? Heart 2008- 94: 1545−7
- De Andrade CA, De Andrade GM, De Paula PM et al. Involvement of central alpha 1-adrenoceptors on renal responses to central moxonidine and alpha-methylnoradrenaline. Eur J Pharmacol. 2009 Apr l-607(l-3):60−7
- De las Fuentes L, Brown AL, Mathews S J et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J. 2007−28:553−559
- De Luca N, Izzo R, Fontana D et al. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine // J. Hypertension. 2000. — Vol. 18. — P. 15 151 522
- De Simone G, Pasanisi F., Contaldo F. Link of nonhemodinamic factors to hemodinamic determinants of left ventricular hypertrophy. Hypartension 2001- 38- 13−18
- De Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006- 17 (8): 2100−5
- Delerme S. Amelioration pression-independante de la distensibilite des gros troncs arteriels par le traitement anti-hypertenseur (DEA de pharmacologie experimental et clinique). Paris: Universite Paris XI- 1997−1998
- Der Sarkissian S, Marchand EL, Duguay D, Hamet P, DeBlois D (2003). Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril. Cardiovasc Res 57: 775 783
- Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation, 1993−88:1444−55
- Diez J., Lopez B., Gonzalez A et al. Clinical aspects of hypertensive myocardial fibrosis. Curr. Opin. Cardiol. 2001−16:328−335
- Doumas MN, Douma SN, Petidis KM et al. Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. J Clin Hypertens (Greenwich) 2004 Dec- 6(12): 682−9
- Draznin B, Sussman KE, Eckel RH et al. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin invest 1988, 82:1848−1852
- Drechsler D. Assessment of Carotid Arteries and Pulse Wave Velocity in Patients with Three-Vessel coronary Artery Disease // Polish. Heart. Journal, 2002- LVII (9): 254−259
- Duran-Perez EG, Almeda-Valdes P, Cuevas-Ramos D et al. Treatment of Metabolic Syndrome Slows Progression of Diabetic Nephropathy. Metab Syndr Relat Disord. 2011 Aug 29
- Dzau V.J., Gibbon G.N. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension, 1991- 18 (Suppl III): III 115—III—121
- Eguchi K, Schwartz JE, Roman MJ et al. Metabolic syndrome less strongly associated with target organ damage than syndrome components in a healthy, working population. J Clin Hypertens (Greenwich). 2007 May-9(5):337−44
- El Ayoubi R, Menaouar A, Gutkowska J et al. Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist. Br J Pharmacol 2005 May- 45 (1): 50−6
- Elisaf M.S., Petris C., Bairaktari E. et al. The effect of moxonidine on plasma lipid profile and on LDL subclass distribution // J. Hum. Hypertension. 1999. — Vol. 13, № 11.-P. 781−785
- Emre A, Oz D, Yesilcimen K, Sayar N et al. Impact of the metabolic syndrome on aortic pulse pressure and ascending aortic pulsatility in patients with angiographically normal coronary arteries. Can J Cardiol. 2009 Jul-25(7):411−4
- Engeli S., Bohnke J., Feldpausch M. et al. Regulation of 1 lbeta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 2004- 12:9−17
- Engeli S., Negrel R., Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000- 35(6): 1270−7.
- Eren M, Gorgulu S, Uslu N et al. Relation between aortic stiffness and left ventricular diastolic function in patients with hypertension, diabetes, or both. Heart. 2004 January- 90(1): 37−43
- Ernsberger P, Ishizuka T, Liu S et al. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 1999- 288: 139P47
- Ernsberger P, Koletsky R, Collins LA et al. Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drugs Ther 1996- 10: 275−82
- Ernsberger P. Pharmacology of moxonidine: and 11 -imidazoline receptor agonist. J Cardiovasc Pharmacol 2000- 35 (7 Suppl. 4): S27−41
- ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J Hypertens 2003- 21: 1011−53
- Farias CA, Rodriguez L, Garcia MJ et al. Assessment of diastolic function by tissue Doppler echocardiography: comparison with standard transmitral and pulmonary venous flow. J Am Soc Echocardiogr. 1999 Aug-12(8):609−17
- Farias CA, Rodriguez L, Garcia MJ et al. Assessment of diastolic function by tissue Doppler echocardiography: comparison with standard transmitral and pulmonary venous flow. J Am Soc Echocardiogr. 1999 Aug-12(8):609−17
- Fernandez MJ, Menendez A, Cimas JE et al. Factors associated with arterial distensibility in hypertension. Aten Primaria, 2000- 25(9):613—617
- Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350−357
- Ferrara LA, Cardoni O, Mancini M et al. Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the GUBBIO Study. J Hum Hypertens. 2007b 0ct-21(10):795−801
- Ferreira I, Boreham CA, Twisk JW et al. Clustering of metabolic syndrome risk factors and arterial stiffness in young adults: the Northern Ireland Young Hearts Project. J Hypertens. 2007 May-25(5): 1009−20
- Ferri C, Desideri G, Valenti M et al. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension 1999- 34, 4 Pt. 1: 568−73
- Filipovsky J. Predictive value of central blood pressure and arterial stiffness for cardiovascular events. In: Laurent S., Cockroft J. Central aortic blood pressure. 2008, 61−67
- Flack JM, Cushman WC. Evidence for the efficacy of low-dose diuretic monotherapy. Am. J. Med.- 1996.- Vol.101.- P.53S-60S. +
- Frei M, Kuster L, Gardosch von Krosigk PP et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994−24 Suppl.l.:S25−8
- Frey N, Katus HA, Olson et al. Hypertrophy of the heart: a new therapeutic target Circulation 2004- 109: 1580 1589
- Friedman JE, Ishizuka T, Liu S et al. Antihyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Blood Press 1998- Suppl 3: 32P9
- Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension. 2010 Apr-55(4):813−8
- Galderisi M, Paolisso G, Tagliamonte MR et al. Is insulin action a determinant of left ventricular relaxation in uncomplicated essential hypertension? J Hypertens 1997, 15:745−50
- Galderisi M, Tagliamone MR, D’Errico A et al. Independent association of plasma leptin levels and left ventricular isovolumic relaxation in uncomplicated hypertension. Am J Hypertens 2001, 14:1019−1024
- Gall MA, Rossing P, Skott P et al. Placebo-controlled comparison of Captopril, metoprolol and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. Amer J Hypertens 1992−5:257−65
- Ganne S, Winer N. Vascular Compliance in the Cardiometabolic Syndrome. J Cardiometab. Syndr. 2008, 3: 35−39
- Gerber LM, Shmukler C, Alderman MH. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects. Arch Intern Med 1992- 152: 373−7
- Gierard X., Giannatasio C., Moulin C. et al. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after longterm antihypertensive treatment: the Pericles study // J. Am. Coll Cardiol, 1998- 31: 1064— 1073
- Giles Th.D., G.E. Sander. Beyond the Usual Strategies for Blood Pressure Reduction: Therapeutic Considerations and Combination Therapies. // J. Clin. Hypertens.- 2001, — Vol.3(6).- P.346−353
- Glasser SP, Arnett DK, McVeigh GE et al. Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens. 1997- 10:1175— 1189
- Gluck Z, Weidmann P, Mordasini R. Increased serum low-density lipoprotein cholesterol in men, treated short-term with diuretic chlortalidone. Metab. 1980- 29:240−5
- Gorzelniak K., Engeli S., Janke J. et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002- 20: 965- 73
- Grandi AM, Maresca AM, Giudici E et al: Metabolic syndrome and morphofunctional characteristics of the left ventricle in clinically hypertensive nondiabetic subjects. Am J Hypertens 2006- 19(2) 199−205
- Grandi AM, Santillo R, Zanzi P et al. Microalbuminuria in nevertreated hypertensives: lack of relationship to hyper-insulinemia and genetic predisposition to hypertension. Am J Hypertens. 2000 Apr- 13(4 Pt l):353−8
- Grassi G Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 2004- 13: 513−519
- Greenwood J.P., Scott E.M., Stoker E. M et al. Chronic II imidazoline agonism: sympathetic mechanisms in hypertension // Hypertension. 2000. -Vol. 35, № 6.-P. 1264−1269
- Gress TW, Neito FJ, Shahar E. et al. Hypertension and antihypertensive therapy as risk factor for type 2 diabetes. N Engl O Med 2000- 342: 905−12
- Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol. 2008−294:F685−696.) (Christine Marie and John E. Obesity, metabolic syndrome and diabetic nephropathy. Contrib Nephrol. 2011- 170: 28−35
- Guembe MJ, Toledo E, Barba J et al. Association between metabolic syndrome or its components and asymptomatic cardiovascular disease in the RIVANA-study. Atherosclerosis. 2010 Aug-211(2):612−7
- Guidelines Committee: 2003 European Society of Hypertension- European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 2003−21:1011−1053
- Giiray Y, Refiker M, Demirkan B et al. Aortic strain and distensibility in patients with metabolic syndrome. Turk Kardiyol Dern Ars. 2010 Jan-38(l):14−9
- Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl 1999- 17 Suppl. 3: S29−35
- Hamdy O, Ledbury S, Mullooly C et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care. 2003 Jul-26(7):2119−25
- Hansson L, Lidholm L, Skbom T. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality the Swedish Trial in Old Patients with Hypertension II Study / // Lancet. — 1999. -№ 354.-P. 1751−1756
- Hansson L. Therapy of hypertension and metabolic syndrome: Today’s Standard and tomorrow’s perspectives // Blood Pressure. 1998. — Vol. 7. (Suppl. 3). — P. 20−22
- Hansson L., Lindholm LH, Ekbom T. et al. Randomozes trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999- 354: 1751−6
- Hashimoto J, Ito S. Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. Hypertension. 2011 Nov-58(5):839−46
- Hayashi K, Ide K, Matsumoto T. Aortic walls in atherosclerotic rabbits-mechanical study. J Biomech Eng. 1994 Aug-l 16(3):284−93
- Hayashi K, Ozawa Y, Fujiwara K et al. Role of actions of calcium antagonists on efferent arterioles with special references to glomerular hypertension. Am J Nephrol 2003- 23: 22914
- Hayden MR, Chowdhury NA, Witte L et al. Microalbuminuria and proximal tubule remodeling in the cardiometabolic syndrome. J Cardiometab Syndr. 2006 Spring- 1(2): 107−14
- Haynes FW. Pulse Wave Velocity and Arterial Elasticity in Arterial Hypertension, Arteriosclerosis, and Related Conditions / F.W. Haynes et al. // Am Heart Journal. 1936.-Vol. 11, № 4. P. 385−401
- Hayward CS, Avolio AP, O’Rourke M.F. et al. Arterial pulse wave velocity and heart rate. // Hypertension. 2002- 40: 8−9
- Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased incidence of coronary heart disease. Arch Intern Med 1993- 153:578
- Henriksen EJ, Jacob S, Fogt DL et al. Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. Hypertension 1997- 30: 1560P5
- Hirai T, Sasayama S, Kawasaki T et al. Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. Circulation, 1989- 80- 78−86
- Hoes AW, Grobbee DE, Lubsen JL, et al. Diuretics, beta blockers, and the risk for sudden cardiac death in hypertensive patients.// Ann. Intern. Med.- 1995.- Vol. 123.-P.481
- Horio T, Suzuki M, Suzuki K et al: Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005- 18: 949−957
- Houston MC. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am heart J 1988- 115- 3: 640−56
- Hunter J.J., Chien K. R. Signaling Pathways for Cardiac Hypertrophy and Failure // New. Engl. J. Med. 1999. — Vol. 341, № 17. — P. 1276−1283
- Hwang YC, Jee JH, Kang M et al. Metabolic syndrome and insulin resistance are associated with abnormal left ventricular diastolic function and structure independent of blood pressure and fasting plasma glucose level. Int J Cardiol. 2011 Mar 9
- Iketani T., Iketani Y., Takazawa K et al. The influence of the peripheral reflection wave on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res, 2000- 23 (5): 451158
- Ishimitsu T, Kobayashi T, Honda T et al. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res2005- 28: 351 359
- Ito H, Ishii K, Kihara H et al. Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. Hypertens Res. 2011 Oct 20
- Ivanovic BA, Tadic MV, Simic DV. Are all criteria of metabolic syndrome equally harmful? Acta Cardiol. 2011 Apr-66(2): 189−96
- Jennings G, Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analysis. J Hypertens. Suppl 1998- 16: S29-S34
- Johnson BF. The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol. 1982- 4 (Suppl.2): 213−21
- Johnston C.J. The place of diuretics in the treatment of hypertension in 1993: Can we do better? Clin, and Exper. Hypertension.- 1993.- Vol.15 (6).- P.1239−1255
- Jones B.H., Standridge M.K., Moustaid N. Angiotensin II increases lipogenesis in3T3-Ll and human adipose cells. Endocrinology 1997- 138: 1512−9
- Jones С A, Francis ME, Eberhardt MS et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002- 39: 445−59
- Kacso I, Lenghel A, Bondor CI et al. Low plasma adiponectin levels predict increased urinary albumin/creatinine ratio in type 2 diabetes patients. Int Urol Nephrol. 2011 Oct 13
- Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney International. 2001 -59(4): 1498−1509
- Karbonits M. Leptin levels do not change acutly with food administration, but area negatively correlated with pituitary activity. О Endocrinol 997- 152: 39
- Karlsson C., Lindell K., Ottosson M. et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998- 83: 3925−9
- Kashyap SR, Roman LJ, Mandarino L et al. Hypoadiponectinemia is closely associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. Metab Syndr Relat Disord. 2010 Oct-8(5):459−63
- Kass DA, Shapiro EP, Kawaguchi M et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001−104:1464−1470
- Kassab S, Kato T, Wilkins С et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995- 25(pt 2): 893 897
- Kenchaiah S., Pfeffer M.A. Cardiac remodeling in systemic hypertension. Med. Clin. North Am. 2004−88:115−130
- Khan AR, Khan MQ. Association and pattern of diastolic dysfunction in patients of metabolic syndrome. J Ayub Med Coll Abbottabad. 2008 Apr-Jun-20(2):70−5
- Kim S., Whelan J., Claycombe K. et al. Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism. J Nutr 2002- 132: 1135−40
- Kim TN, Park MS, Lim KI et al. Skeletal muscle mass to visceral fat area ratio is associated with metabolic syndrome and arterial stiffness: The Korean Sarcopenic Obesity Study (KSOS). Diabetes Res Clin Pract. 2011 Aug-93(2):285−91
- Kim YI, Kim CH, Choi CS et al. Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 dia-betes in the Korean population. Diabetes Res Clin Pract. 2001 May-52(2): 145−52
- Kincaid-Smith P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end stage renal failure attributed to hypertension and labeled «hypertensive nephrosclerosis». J Hypertens 2004- 22: 1051−5
- King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008−79:1527−1534
- Kirch W, Hutt HJ, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. J Clin Pharmacol 1990- 30: 1088−95
- Kirch W, Hutt HJ, Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988 Oct- 15 (4): 245−53
- Kistorp C, Raymond I, Pedersen F et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005- 293 (13): 1609−16
- Klingbeil AU, Schneider M, Marius P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003- 115 (1): 41−6
- Koh KK, Han SH, Ahn JY et al. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol 2009- 133 (1): 2331
- Konta T, Hao Z, Abiko H et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. Kidney Int 2006- 70: 751−6
- Kool M.J., Lustermans M.A., Breed J.G. et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorthiazide on the vessel wall properties of large arteries in hypertensive patients // J. Hypertens, 1995- 13: 839−848
- Kotsis V, Stabouli S, Pitiriga V et al. Ambulatory blood pressure monitoring and target organ damage: effects of age and sex. Blood Press Monit. 2006 Feb- 11(1):9−15
- Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol 1994, 24 (Suppl 1): S29-S33
- Krespi PG, Makris TK, Hatzizacharias AN et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998 Oct- 12: 463−7
- Krupicka J, Soucek M, Chroust K. The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial). Vnitr Lek. 2011 Jun-57(6):541−5
- Kullo I, Bielak L, Turner S et al. Aortic pulse wave velocity is associated with the presence and quantity of coronary artery calcium. Hypertension 2006- 47: 174
- Kuppers HE et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997- 15: 93−7
- Lambert E, Straznicky NE, Dawood T et al. Change in sympathetic nerve firing pattern associated with dietary weight loss in the metabolic syndrome. Front Physiol. 2011−2:52
- Landsberg L. Pathophysiology of obesityrelated hypertension. Role of insulin and sympathetic nervous system. J Cardiovasc Pharmacol 1994- 23 (Suppl 1): S1-S8
- Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006- 21: 2588−605
- Laville M. Renal consequences of obesity. Nephrol Ther. 2011 Apr-7(2):80−5
- Lehmann E.D. Arterial wall compliance in diabetes. Diabet Med., 1992- 9(2): 114−119
- Leoncini G, Ratto E, Viazzi F et al. Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension. Hypertension. 2006 Sep-48(3):397−403
- Levisianou D, Melidonis A, Adamopoulou E et al. Impact of the metabolic syndrome and its components combinations on arterial stiffness in Type 2 diabetic men. Int Angiol. 2009 Dec-28(6):490−5
- Li AE, Kamel I, Rando F et al. Using MRI to assess aortic wall thickness in the multiethnic study of atherosclerosis: distribution by race, sex, and age // Am. J. Roentgenol, 2004- 182(3): 593−597
- Lian YK, Li HW, Wu YQ et al. The relationship between left ventricular diastolic function and arterial stiffness in diabetic coronary heart disease. Zhonghua Nei Ke Za Zhi. 2011 Aug-50(8):676−9
- Liao D, Arnett DK, Tyroler HA et al. Arterial stiffness and the development of hypertension: the ARIC study. Hypertension. 1999−34:201−206
- Lieb W, Mayer B, Stritzke J et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: The MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant 2006- 21 (10): 2780−7
- Liese AD, Hense HW, Brown AA et al. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001- 15: 799−804
- Lithell H. Selective improvement in insulin sensitivity with moxonidine. Satellite Symposium of XIX Congress of Eur. Soc. Cardiology, Stockholm, 1997, 1−8
- Lu H., Boustany-Kari C.M., Daugherty A et al. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007- 292: 1280−7
- Mahmud A., Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition // Am. J. Hypertens, 2002−15:321−325
- Massiera F., Bloch-Faure M., Ceiler D. et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001- 15: 2727−9
- Masson S, Chimenti S, Salio M et al. (2001). CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload. Cardiovasc Drugs Ther 15: 131 138
- Masugata H, Senda S, Goda G et al. Left Ventricular Diastolic Dysfunction as Assessed by Echocardiography in Metabolic Syndrome. Hypertension Research (2006) 29, 897−903
- Masuo K. Obesity-related hypertension: role of the sympathetic nervous system, insulin, and leptin. Curr Hypertens Rep 2002- 4: 112−8
- Mattace-Raso FU, Van Der Cammen TJ, Hofman A et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006- 113(5):657−663
- McEleavy O.D., McCallum R.W., Petrie J.R. et al. Higher carotidradial pulse wave velocity in healthy offspring of patients with Type 2 diabetes. Diabetic Medicine, 2004- 21(3): 262−266
- McEniery C.M., Yasmin, Hall I.R. et al. Normal vascular aging: differential effect on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT) // J. Am. Coll Cardiol, 2005- 46:1753−1760
- McLenachan JM, Henderson E, Morris KI et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. // N. Engl. J. Med.- 1987.-Vol.317.- P.787
- Menaouar A, El-Ayoubi R, Jankowski et al. Chronic imidazoline receptor activation in spontaneously hypertensive rats. Am J Hypertension 2002- 15: 803 -808
- Messerli F. Moxonidine: a new and versatile antihypertensive. J Cardiovasc Pharmacol 2000- 35 (7 Suppl 4): S53 S56
- Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med. 2011 Oct- 124(10):896−9
- Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as firstline therapy for hypertension in the elderly? a systematic review.// JAMA.- 1998.-Vol.279.- P. 1903−1907
- Messerli FH, Nunez BD, Nunez MM et al. Hypertension and sudden death. Disparate effects of calcium entry blockers and diuretic therapy on cardiac dysrhythmias. //Arch. Intern. Med.- 1989.- Vol.149.- P. 1263
- Mitchell G, Parise H, Benjamin E. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women. The Framingham Heart Study. Hypertension 2004- 43: 123913
- Mitrovic V, Patyna W, Huting J et al. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991 Dec- 5 (6): 967−72
- Mogensen CE. The kidney in diabetes: how to control renal and related cardiovascular complications. Am J Kidney Dis 2001- 37: S2-S
- Morales E, Valero MA, Leon M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. American Journal of Kidney Diseases. 2003−41(2):319−327
- Morgan T, Lauri J, Bertram D et al. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004- 17:118−123
- Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Hannover: Solvay Pharmaceuticals, 2005. Data on file
- Mule G, Cerasola G. The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens (Greenwich). 2006 Mar-8(3): 195−201
- Mule G, Cottone S, Mongiovi R et al. Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients. Nutr Metab Cardiovasc Dis. 2006 Jan-16(l):54−9
- Mykkanen L, Zaccaro DJ, Wagenknecht LE et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the Insulin Resistance Aterosclerosis Study. Diabetes 1998- 47: 793−800
- Nagueh SF, Appleton CP, Gillebert TC et al. Recommendation for the Evaluation of left ventricular diastolic function by echocardiography. Eur J Cardiol 2009- 10: 165−193
- Navarro J, Redon J, Cea-Calvo L et al. Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERICHTA study. Blood Press. 2007−16(l):20−7
- Nelson AJ, Worthley SG, Cameron JD et al. Cardiovascular magnetic resonance-derived aortic distensibility: validation and observed regional differences in the elderly. J Hypertension 2009- 27: 535−542
- Neutel JM. Metabolic manifestations of low-dose diuretics. Am. J. Med.-1996,-Vol.101.-P.71S-82S
- Nichols W.W., O’Rounkle M.F. McDonald’s Blood Flow in Arteries: Theoretical, Experimental and Clinical Principals. 4th edition. London: Arnold, 1998
- Nieuwdorp M, Mooij HL, Kroon J et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006- 55 (4): 1127−32
- Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004- 292 (18): 2217−25
- Ochodnicky P, Henning RH, van Dokkum RP et al. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. Cardiovasc Pharmacol 2006- 47 (Suppl. 2): SI51−62
- Ogawa T, Shimada M, Ishida H et al. Relation of stiffness parameter beta to carotid arteriosclerosis and silent cerebral infarction in patients on chronic hemodialysis. Int Urol Nephrol. 2009−41(3):739−45
- Ogawa Y. CNS. Mediators of leptin action. Presented at 60-th Scientific Sessions of the American diabetes association. June 13, 2000, San Antonio, Texas
- Ogihara T, Fujimoto A, Nakao K et al. CASE-J Trial Group/ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008- 6 (9): 1195−201
- Ohmori K., Emura S., Takashima T. Risk factors of atherosclerosis and aortic pulse wave velocity. Angiology, 2000- 51(1): 53−60
- Ohshita K, Yamane K, Ishida K et al. Post-challenge hyperglycaemia is an independent risk factor for arterial stiffness in Japanese men. Diabet Med. 2004−21(6):636−639
- Okin PM, Devereux RB, Jern et al .(LIFE Study Investigators) Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004- 292: 2343 2349
- Okuyama H, Hirono O, Tamura H et al. Impact of aortic arch stiffness on recurrence of stroke in patients with acute ischemic stroke. Circ J. 2008 Aug-72(8): 1296−302
- Orynchak MA, Neyko EM, Chovganyuk OS. Role of moxonidine in insulin secretion and endothelial dysfunction in the patients with insulin resistance abstract no. P-538. Am J Hypertens 2005 May 2- 18 (5): 202−3
- Papafragkaki DK, Tolis G. Obesity and renal disease: a possible role of leptin. Hormones. 2005−4(2):90−95
- Paquette P.-A., Duguay D., Ayoubi, RE et al. Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation. British Journal of Pharmacology, 2008- 153: 459−467
- Paul M., Mehr A.P., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006- 86: 747−803
- Pedrinelli R, Dell’Omo G, Di Bello V et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vase Biol 2004- 24 (12): 2414−9
- Pedrinelli R, Giampietro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994- 344: 14—8
- Pelayo JC, Westoo JY. Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. J Clin Invest 1991- 88: 101−5)
- Peng H, Carretero OA, Vuljaj et al. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 2005- 112: 2436 2445
- Peng H, Carretero OA, Vuljaj N, Liao TD, Motivala A, Peterson EL et al. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 2005- 112: 2436−2445
- Peng H, Carretero OA, Vuljaj N et al. (2005). Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 112: 2436 2445
- Perseghin G, Ntali G, De Cobelli F et al. Abnormal left ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance Diabetes Care. 2007 Jun-30(6): 1520−6.
- Pinthong D, Songsermsakul P, Rattanachamnong P et al. The effects of imidazoline agents on the aggregation of human platelets. J Pharm Pharmacol 2004 Feb- 56 (2): 213−20
- Pollare T, Lithell H., Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. //New Engl. J. Med.- 1989.- Vol. 321.- P.868
- Prichard B.N., Graham B.R., Owens C.W. Moxonidine: a new antiadrenergic antihypertensive agent // J. Hypertension. 1999. — Vol. 17 (Suppl. 3). — P. 41−45
- Prichard BNC, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertens 1997 Jan- 15 Suppl. 1: 47−55
- Prichard BNC, Simmons R, Rooks M et al. A double-blind comparison of moxonidine and atenolol in the management of patiens with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992, 24 (Suppl 4): S45-S49
- Protogerou AD, Blacher J, Aslangul E et al. Gender influence on metabolic syndrome’s effects on arterial stiffness and pressure wave reflections in treated hypertensive subjects. Atherosclerosis. 2007 Jul- 193(1): 151−8.
- Psaty BM, Smith NZ, Siskovick DS et al. Health outcomes associated with antihypertensive agents. A systematic review and metaanalysis. // JAMA. 1997 Vol.277 (9)739−745
- Rahn K. On behalf of the ELS A investigators. The European Lacidipin Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and cj-relations with risk factors J. Hypertens. 1998. -№ 16. — P. 31−33
- Resnick L. The cellular ionic basis of hypertension and allied clinical conditions. Prog Cardiovasc Dis 1999- 42 (1): 1−22
- Resnick, L. M. Ionic basis of hypertension, insulin resistance, vascular disease and related disorders Am. J. Hypertension. 1993. — V. 6. — № 4. -P. 123- 124
- Rosen P, Ohhy P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-ied rat. J Hypertens 1997- (Suppl 15):S31-S38
- Routledge FS, McFetridge-Durdle MA, Dean CR. The effect of nondipper blood pressure pattern on target organ damage in patients with metabolic syndrome. Can J Cardiol > v.23(2) — Feb 2007
- Rumantir MS, Vaz M, Jennings G et al. Neural mechanisms in human obesity-related hypertansion. J Hypertens 1999- 17: 1125−1133
- Rutter MK, Parise H, Benjamin EJ et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003- 107:44854
- Sa Cunha R., Pannier В., Benetos A. et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. Journal of Hypertension 1997- 15, 1423—1430
- Safar ME, Levy BI, Struiker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003−107:2864−2869
- Safar ME, London GM. Therapeutic studies and arterial stiffness in hypertension: Recommendations of the European Society of Hypertension //J. Hypertens, 2000- 18: 1527−1535.
- Safar ME, Thomas F, Blacher J et al. Metabolic syndrome and age-related progression of aortic stiffness. J Am Coll Cardiol. 2006 Jan 3−47(l):72−5
- Saint-Marc P, Kozak LP, Ailhaud G et al. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001- 142: 487−92
- Saitoh M, Nishimura H, Tanaka T et al. Gender-related differences in target organ damage in untreated patients with essential hypertension. Intern Med. 2006−45(6):377−83
- Sarzani R, Savi F, Dessi-Fulgheri P et al. Renin-angiotensin system, natrriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in human. J Hypertens 2008- 26: 831−43
- Satoh N, Ogawa Y, Usui T et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003−26:2493−2499
- Satoh N, Shimatsu A, Kato Y et al. Evaluation of the cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome. Hypertens Res. 2008 Oct-31(10): 1921−30
- Schaefer HG, Toublanc N, Weimann H-J. The pharmacokinetics of moxonidine. Rev Contemp Pharmacother 1998- 9 (7): 481−90
- Schlachter M. Moxonidine: a review of safety and tolerability after seven years of clinical experience. J. Hypertension. 1999. — Vol. 17 (Suppl. 3). — P. 37−39
- Schlaich MP, Kaye DM, Lambert E et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003- 108: 560−565
- Schmeider RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy: analysis of 412 published studies. Am J Hypertens 1994- 7: 25 A
- Schmeider RE, Schilachi MP, Klingbeil A et al. Update of Reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996) Nephrol Dial Transplant 1998- 13: 564−9
- Schmidt MI, Duncan BB, Bang H et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005- 28:2013−2018
- Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. //JAMA.- 1996, — Vol.275.- P. 1507
- Schram MT, Henry RM, van Dijk RA et al. Increased central arterial stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn study. Hypertension, 2005−43:176−181
- Schram MT, Schalwijk CG, Bootsma AH et al. Advanced glycation end products are associated with pulse pressure in type 1 di8abetes: the EURODIAB Prospective Complications Study. Hypertension, 2005- 46: 232−237
- Schulman IH, Zachariah M, Raij L. Calcium channel blockers, endothelial dysfunction, and combination therapy. Aging Clin Exp Res 2005- 17 (4 Suppl.): 40−5
- Scuteri A, Najjar SS, Muller DC et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol. 2004 Apr 21 -43(8): 1388−95
- Scuteri A, Orru M, Morrell C et al. Independent and additive effects of cytokine patterns and the metabolic syndrome on arterial aging in the SardiNIA Study. Atherosclerosis. 2011 Apr-215(2):459−64
- Serazin V., Dos Santos E., Morot M et al. Human adipose angiotensinogen gene expression and secretion are stimulated by cyclic AMP via increased DNA cyclic AMP responsive element binding activity. Endocrine 2004- 25: 97−104
- Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: A meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2011 Dec 9
- Shankar SS, Steinberg HO. Obesity and endothelial dysfunction. Semin Vase Med 2005- 5: 56−64
- Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens 2004 Sep- 18 (9): 669−75
- Sheng CS, Hu BC, Fan WX et al. Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population. Diabetol Metab Syndr. 2011 Apr 7−3(1):6
- Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and arrhythmias in hypertensive men. // JAMA. 1992.-Vol.267,-P.1083
- Simkova A, Bulas J, Murin J et al. Metabolic syndrome and aortic stiffness. Vnitr Lek. 2010 Sep-56(9 Suppl): 1000−4
- Singal T, Dhalla NS, Tappia PS. Phospholipase C may be involved in norepinephrine-induced cardiac hypertrophy. Biochem Biophys Res Commun 2004- 320: 1015- 1019
- Sipahi I, Tuzcu EM, Schoenhagen P et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006- 48 (4): 833−8
- Sowers JR. Metabolic risk factors and renal disease. Kidney int. 2007- 71:719 720
- Strojek K, Grzeszczak W, Grska J et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001 Mar- 12: 602−5
- Stumvoll M, Jacob S. Multiple sites of insulin resistance: muscle, liver and adipose tissue. Exp Clin Endocrinol Diabetes 1999- 107: 107P10
- Sun Z, Ernsberger P. Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. J Pharmacol febr. 2007- 320 (2) :845−52
- Tada Y, Kagota S, Matsumoto M et al. Characterization of cardiac size and function in SHRSP. Z-Lepr (fa)/IzmDmcr rats, a new animal model of metabolic syndrome. Biol Pharm Bull. 2010−33(12): 1971−6
- Takazawa K., Tanaka N., Fujita M. et al. Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. Hypertension, 1998- 32: 365−370
- Tarif N, Bakris GL. Preservation of renal function: The spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997- 12: 2244−50
- Taviani V, Hickson S, Hardy Ch et al. Age-related changes of regional pulse wave velocity in the descending aorta using fourier velocity encoded M-mode. Magnetic Resonance in Medicine 2011- 65: 261−8
- Tea BS, Dam TV, Moreau P et al. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats: temporal regulation and spatial heterogeneity. Hypertension 1999- 34: 229 235
- Terpstra, May JF, Smith AJ. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the EL VERA trial) / W. E. // J. Hypertens. 2004. — V. 22. — № 7. — P. 1309−16
- Tesauro M, Canale MP, Rodia G et al. Metabolic Syndrome, Chronic Kidney, and Cardiovascular Diseases: Role of Adipokines. Cardiol Res Pract. 2011- 2011: 653 182
- The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI) // Arch Intern Med.-1997,-Vol.157.- P.2413−2446
- Thomas G, Sehgal AR, Kashyap SR et al. Metabolic Syndrome and Kidney Disease: A Systematic Review and Meta-analysis. Clin J Am Soc Nephrol. 2011 Oct-6(10):2364−73
- Throckmorton DC, Brogden AP, Min B et al. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int. 1995−48:111−117
- Ting CT, Chen CH, Chang MS et al. Short- and long-term effects of antihypertensive drugs on arterial reflections, compliance and impedance. Hypertension, 1995- 26: 524−530
- Tomiyama H, Yamashina A, Arai T et al. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement a survey of 12 517 subjects. Atherosclerosis, 2003- 166(2): 303−309
- Tomochika Y, Okuda F, Tanaka N et al. Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia. Arterioscler Thromb Vase Biol. 1996 Aug-16(8):955−62
- Topouchian J, Asmar R, Sayegh F et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke, 1999- 30:1056−1064
- Toto-Moukouo J, Achimastos A, Asmar RG et al. Pulse wave velocity in patients with obesity and hypertension. American Heart Journal, 1986- vol. 112, no. 1, pp. 136−140
- Trimarco B, De Luca N, Ricciardelli B et al. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol 1998- 62: 745−750
- Triposkiadis F, Kallikazaros I, Tricas A et al. A comparative study of the effect of coronary artery disease on ascending and abdominal aorta Distensibility and pulse wave. Velocity Acta Cardiologica 1993- 2: 221−33
- Troussov V, Acsenov C. Moxonidine (Phisiotens) in treatment of hypertension in elderly patients with type 2 diabetes meltinus abstract no. 2543. Diabetes Metab 2003 Aug- 29 (4 Suppl.): 314
- Tsioufis C, Dimitriadis K, Taxiarchou E et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 2006- 19 (5): 462−6
- Tsioufis C, Tsiachris D, Dimitriadis K et al. Evidence for no global effect of metabolic syndrome per se on early hypertensive sequelae. J Hypertens. 2008 Apr-26(4):773−9
- Tsuji T, Mizushige K, Noma T et al. Improvement of aortic wall distensibility and reduction of oxidative stress by pioglitazone in pre-diabetic stage of Otsuka Long-Evans Tokushima fatty rats. Cardiovasc Drugs Ther. 2002 Sep-16(5):429−34
- Urbina EM, Gao Z, Khoury PR et al. Insulin resistance and arterial stiffness in healthy adolescents and young adults. Diabetologia. 2012 Mar-55(3):625−31
- Urbina EM, Srinivasan SR, Kieltyka RL et al. Correlates of carotid artery stiffness in young adults: the Bogalusa Heart Study. Atherosclerosis. 2004- 176:157 164
- Valensi P, Assayag M, Busby M et al. Microalbuminuria in obese patients with or without hypertension. Int J Obesity 1996- 20: 574−9
- Van Popele NM, Grobbee DE, Bots M et al. Association Between Arterial Stiffness and Atherosclerosis. Stroke, 2001- 32: 454−460
- Van Popele NM, Westendorp IC, Bots ML et al. Variables of the insulin resistance syndrome are associated with reduced arterial distensibility in healthy non-diabetic middle-aged women. Diabetologia. 2000−43:665−672
- Varo N, Etayo JC, Zalba G et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999- 17: 107 114
- Vaz M, Jennings G, Turner A et al. Regional sympathetic nervous activity and oxygen consuption in obese normotensive human subjects. Circulation 1997- 96: 3423−3429
- Verdecchia P, Schillaci G, Borgioni C et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995, 25:871−878
- Viazzi F, Leoncini G, Parodi D et al. Impact of Target Organ Damage Assessment in the Evaluation of Global Risk in Patients with Essen-tial Hypertension. J Am Soc Nephrol 2005- 16: S89-S91
- Vyssoulis GP, Pietri PG, Karpanou EA et al. Differential impact of metabolic syndrome on arterial stiffness and wave reflections: focus on distinct definitions. Int J Cardiol. 2010 Jan 21 — 138(2): 119−25
- Wada T, Fujishiro K, Fukumoto T et al. Relationship between ultrasound assessment of arterial wall properties and blood pressure. Angiology. 1997 0ct-48(10):893−900
- Wake D.J., Walker B.R. Inhibition of 1 lbeta-hydroxysteroid dehydrogenase type 1 in obesity. Endocrine 2006- 29: 101−8
- Wann-Chu Huang, Te-Chao Fang, Juei-Tang Cheng. Renal denervation prevents and reverses hyperinsulinemia-indused hypertention in rats. Hypertention 1998- 32: 249−254
- Warram JH, Zaffel ZMB, Valsania P et al. Excess mortality associated with diuretic therapy in diabetes mellitus. // Arch. Intern. Med.- 1991.- Vol.151 (7).-P.1350−1356
- Watanabe G., Lee R.J., Albanese C., et al. Angiotensin II activation of cyclin D1-dependent kinase activity. J Biol Chem 1996- 271: 22 570−7
- Watanabe H, Obtsuka S, Kakibana M et al. Coronary circulation in dogs with an experimental decrease in aortic compli-ance. J Am Col Cardiol 1993- 21: 1 497 506
- Waters J, Ashford J et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension: results of the TOPIC (Trial Of Physiotens In Combination) study. J Clin Basic Cardiol 1999- 2 (2): 219−24
- Wenzel UO, Troschau G, Schoeppe W et al. Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992- 20: 233−41
- Wing LMH, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting-enzime inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 2003- 348: 583−592 5
- Winlove CP, Parker KH, Avery NC et al. Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties. Diabetologia. 1996−39:1131−1139
- Wright JM, Lee Ch, Chambers GK. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a firstline drug? // CMAJ.- 1999.-Vol.161.- P.25−32
- Wright JTJr, Agodoa L, Contreras G et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002- 162(14): 1636−43
- Yakubu-Madus FE, Johnson WT, Zimmerman KM et al. Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes 1999- May 48: 1093P100
- Yasunari K, Maeda K, Nakamura M et al. Left ventricular hypertrophy and angiotensin II receptor blocking agents. Curr Med Chem Cardiovasc Hematol Agents 2005- 3: 61 -67
- Yottdiener J.S., Reda D.J., Massic B.M. et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. // Circulation.-1997.- Vol.95 (8).- P.2007−2014
- Zang SL, Chen X, Hsieh TJ et al. Hyperglycemia induces insulin resistance on angiotensinogen gene expression in diabetic rat kidney proximal tubular cells. J Endocrinol 2002- 172 (2): 333−344
- Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol. 2004−15:S55−57
- Zucchelli P, Zuccala A, Borghi M et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992−42:452−8